Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.[1][2][3]
Background
Valneva was founded in 2013 through the merger of Austrian company Intercell and French company Vivalis SA.[4][5] It has been listed since May 2013 on Euronext Paris Paris and since May 2021 on the US Nasdaq.